A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 601–649 of 649
Pagnoux, C., & Mallet, V. O. (2010) · Elsevier eBooks · doi:10.1016/b978-2-294-71107-7.50058-5
Pulmonary Angiogenesis in Neoplastic and Nonneoplastic Disorders
Keane, M. P., & Strieter, R. M. (2008) · Molecular pathology library · doi:10.1007/978-0-387-72430-0_19
Short-term Clinical Experience on Interferon gamma-1b Therapy for Idiopathic Pulmonary Fibrosis
Hwang, J. H., Chung, M. P., Kang, E. H., Kim, K. C., Lee, B., Koh, W. J., Suh, G. Y., Kim, H., Lee, K. S., Han, J., et al. (2004) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2004.56.6.619
Lewis, K. L. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70111-7
Interférons : utilisation thérapeutique
Brihaye, B., & Papo, T. (2009) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(09)49789-8
Schmidt, S. L., & Flaherty, K. R. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201007-053tt
“Post hoc analyses of the first large trial of IFN g-1b (IFNg) suggested a mortality benefit for patients with mild lung dysfunction (15).”
MethodNew Treatments for Idiopathic Pulmonary Fibrosis
Montero-Martínez, C. (2006) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(06)60105-5
3. Clinical Practice of Interstitial Lung Disease
Nukiwa, T. (2009) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.98.2112
Final Tips in Interpreting Evidence-Based Medicine
Mansi, I. A., Thompson, J. C., & Banks, D. E. (2012) · Southern Medical Journal · doi:10.1097/smj.0b013e318249c152
“5% improvement in progression-free survival.(34) A meta-analysis that included patients from exploratory subgroups identified favorable results,(31)”
MethodFibrosis pulmonar idiopática. Nuevas terapéuticas y evidencia científica
Espinosa, Á. C., & Ancochea, J. (2007)
びまん性肺疾患:診断と治療の進歩 III.最近の話題 6.特発性肺線維症の新しい治療薬
安良太, 吾. (2006) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.95.1069
Une nouvelle classification des pneumopathies interstitielles idiopathiques
Crestani, B. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)71281-4
ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES
Ferrara, G., & Sköld, M. C. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814656337_0012
Idiopaatiline kopsufibroos – äsjane kannapööre ravistrateegias uute lootuste nimel
Altraja, A. (2013) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.11452
Environment and the Role of Inflammation in Chronic Pulmonary Diseases: The Silent Mediator
Yao, H., & Rahman, I. (2011) · Oxidative stress and disease · doi:10.1201/b11014-4
INVITED REVIEW SERIES: PULMONARY FIBROSIS
Kolb, M. R. J., Cox, G., & Behr, J. (2009)
Blandinières, A. (2018) · theses.fr (ABES) · doi:10.70675/9178d6fcz7e4ez48deza1dcz0840f8c96b22
The Pathogenesis of Intraabdominal Adhesions: Similarities and Differences to Luminal Fibrosis
Macarak, E. J., & Rosenbloom, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_22
Immunologic Lung Disease in the Critically Ill
Schmidt, G. A., & Hunninghake, G. W. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50052-2
A Risk-Based Paradigm of Biomarkers in Clinical Trials
Parker, J. L., Domazetoski, E., Bureau, M., Lopes, G. D. L., Jr., Kuzulugil, S. S., & Mitsakakis, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813539-6.00021-3
Erkrankungen der Atmungsorgane
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50007-8
Is Immune Response Relevant in Interstitial Lung Disease?
Khan, M. M. (2020) · Current Immunology Reviews · doi:10.2174/1573395516999200914143054
Idiopathic Pulmonary Fibrosis Clinical Trials: Evolving Concepts
Martínez, F. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_20 · Cited by 1
Sime, P. J., Kottmann, R. M., Lakatos, H. F., & Thatcher, T. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-292-2_40
Pulmonary Diseases: Polymeric Gene Delivery Carriers
Gao, X., Vollmer, R. R., & Li, S. (2016) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052277
Rosenkranz, G. (2019) · Wiley eBooks · doi:10.1002/9781119536734.ref
Ghoshoon, M. B., Nezafat, N., Ghoshoon, N., Ghasemi, Y., & Jahandar, H. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220408135018
Pneumopathies interstitielles diffuses
Nunès, H., & Uzunhan, Y. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70041-0
Ellenberg, S. S., Fleming, T. R., & DeMets, D. L. (2019) · Wiley eBooks · doi:10.1002/9781119512684.ch11
ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50006-6
Raghu, G., & Johnson, W. C. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00023406
Self-citationPneumopathies interstitielles idiopathiques
Nunès, H. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)71526-0
Vogelmeier, C. F., & Behr, J. (2006) · Springer eBooks · doi:10.1007/3-540-26504-x_24
Poor Choice of Primary Outcome in a Clinical Trial of Pirfenidone in Patients with IPF
Raghu, G. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.172.9.952
Self-citationPharmacological Treatment of Idiopathic Pulmonary Fibrosis – An Update
Spagnolo, P., Nunès, H., & Wuyts, W. A. (2013) · EMJ Respiratory · doi:10.33590/emjrespir/10314639
Akbari, N., Haddad, R., Japelaghi, R. H., & Gheibi, N. (2023) · مهندسی ژنتیک و ایمنی زیستی. · doi:10.61186/gebsj.12.2.262
Singh, R. K., Pradhan, A. K., Roy, D., Arya, M., Chakravarti, R., Dutta, D., Kundu, A., Bhaduri, S., Singh, P., Kazi, T. A., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108519
Idiopathic and Autoimmune Interstitial Lung Disease
Gelbman, B. D., & Crystal, R. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00074-5
Wells, A. U., Jacob, J., Sverzellati, N., Cross, G., Barnett, J. L., Lauretis, A. D., Antoniou, K., Weycker, D., Atwood, M., Kirchgaessler, K.-U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25025885
Role of lung nociceptors during pulmonary fibrosis
Hiroki, C. H. (2025) · doi:10.11575/prism/50642
Volfson-Sedletsky, V., DeBerg, H. A., Fahning, M. L., Rifkin, I. R., Bujor, A. M., Campbell, D. J., Morawski, P. A., Belkina, A. C., & Dooms, H. (2026) · The Journal of Immunology · doi:10.64898/2025.12.10.693457 · Cited by 2
Zhu, Y., Ke, Z., Zhang, T., Sun, S. X., & Fan, X. Q. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135124
Athavale, T., Jaiswal, P., Athavale, A., Samant, T., Tipnis, T., Neman, N., Jose, A., Khatri, R., Chougule, D., Joshi, T., et al. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109206
Fibrose pulmonaire idiopathique Usual interstitial pneumonia
Ocmant, A., Place, S., Remmelink, M., Mascart, F., & Cogan, E. (2004)
Interstitielle Lungenerkrankungen
Behr, J. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50109-6
Vuorinen, K. (2008) · Helda - University of Helsinki Institutional Repository
Idiopathic pulmonary fibrosis: clinical impact of different phenotypes
Balestro, E. (2013) · DSpaceUnipr (University of Parma)
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.